Molecular identification of SARS-CoV-2 variants of concern at urban wastewater treatment

plants across South Africa 2

1

- 3 Mukhlid Yousif^{1,2,#}, Said Rachida¹, Setshaba Taukobong¹, Nkosenhle Ndlovu¹, Chinwe Iwu-Jaja¹,
- 4 Wayne Howard¹, Shelina Moonsamy¹, Nompilo Mhlambi¹, Sipho Gwala¹, Joshua I. Levy³, Kristian G.
- Andersen³, Cathrine Scheepers⁴, Anne von Gottberg^{5,6}, Nicole Wolter^{5,6}, Arshad Ismail^{7,8}, Melinda 5
- Suchard⁹, Kerrigan McCarthy^{1,10} for the SACCESS network. 6
- 7 ¹Centre for Vaccines and Immunology, National Institute for Communicable Diseases, a division of the
- 8 National Health Laboratory Service, South Africa
- 9 ²Department of Virology, School of Pathology, Faculty of Health Sciences, University of the
- 10 Witwatersrand, Johannesburg
- ³Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, 11
- USA 12
- ⁴SAMRC Antibody Immunity Research Unit, Faculty of Health Sciences, University of the 13
- 14 Witwatersrand, Johannesburg, South Africa.
- ⁵Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases, a 15
- 16 division of the National Health Laboratory Service, South Africa
- 17 ⁶School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg,
- South Africa. 18
- 19 ⁷Sequencing Core Facility, National Institute for Communicable Diseases, a division of the National
- Health Laboratory Service, South Africa. 20
- ⁸Department of Biochemistry and Microbiology, Faculty of Science, Engineering and Agriculture, 21
- 22 University of Venda, Thohoyandou, South Africa.
- ⁹Department of Chemical Pathology, School of Pathology, University of the Witwatersrand, 23
- Johannesburg. 24

26

25 ¹⁰School of Public Health, University of the Witwatersrand, Johannesburg #Corresponding author

28 Dr Mukhlid Yousif

27

36

39

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

- 29 Centre for Vaccines and Immunology
- 30 National Institute for Communicable Diseases
- 31 Researcher, Virology department
- 32 Faculty of Health Sciences
- 33 University of the Witwatersrand
- 34 Tel: +27 11 386 6461
- Email: mukhlidy@nicd.ac.za, Mukhlid.yousif@gmail.com
- 37 **Keywords:** environmental, wastewater, mutations, sequence, whole genome sequencing, SARS-CoV-
- 38 2, COVID-19, surveillance, minor, spike, alpha, beta, delta, omicron, C1.2
- 40 Abstract

The use of wastewater for SARS-CoV-2 surveillance is a useful complementary tool to clinical surveillance. The aims of this study were to characterize SARS-CoV-2 from wastewater samples, and to identify variants of concern present in samples collected from wastewater treatment plants in South African urban metros from April 2021 to January 2022. A total of 325 samples were collected from 15 wastewater treatment plants. Nucleic acids were extracted from concentrated samples, and subjected to amplicon-based whole genome sequencing. To identify variants of concerns and lineages, we used the Freyja tool (https://github.com/andersen-lab/Freyja), which assigns each sample with the prevalence of each variant present. We also used signature mutation analysis to identify variants in each wastewater treatment site. A heatmap was generated to identify patterns of emerging mutations in the spike gene using Excel conditional formatting. Using the Freyja tool, the Beta variant was detected and became predominate from April to June 2021 followed by the Delta variant and lastly the Omicron variant. Our heatmap approach was able to identify a pattern during the changes of predominate variant in wastewater with the emergence of mutations and the loss of others. In conclusion, sequencing of SARS-CoV-2 from wastewater largely corresponded with sequencing from clinical specimens. Our heatmap has the potential to detect new variants prior to emergence in clinical samples and this may be particularly useful during times of low disease incidence between waves, when few numbers of positive

- 57 clinical samples are collected and submitted for testing. A limitation of wastewater sequencing is that
- 58 it is not possible to identify new variants, as variants are classified based on known mutations in clinical
- 59 strains.

Background

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

As SARS-CoV-2 is shed into stool and urine, and is detectable in wastewater 1, quantification and sequencing of SARS-CoV-2 in wastewater has the potential to overcome inherent limitations in clinically-based epidemiological approaches. Over the pandemic, clinical surveillance has relied on testing and sequencing of samples from infected individuals. However, when clinical testing forms the basis for surveillance, population health seeking behaviour, test accessibility and testing practices of attending clinicians limit the generalisability of data. In particular, only symptomatic patients approach the health system for testing and testing practices vary by location and over time ², leading to an incomplete representation of local virus spread and diversity. Testing of wastewater for SARS-CoV-2 levels overcomes these limitations by allowing population levels of SARS-CoV-2 to be monitored over time and by location, adding key information to our understanding of SARS-CoV-2 transmission dynamics. The value of wastewater monitoring of SARS-CoV-2 is attested to by the fact that over 70 countries now provide monitoring and public reporting of geographical and temporal trends in wastewater levels 3 4 Wastewater genomic surveillance offers an opportunity to monitor circulating variants present in the community. Whole genome sequencing ⁵, and other methods such as real-time PCR ⁶ enable detection and characterisation of SARS-CoV-2 variants, and have now been applied to wastewater samples. Recent work has shown the potential for recovery of complete virus genomes from wastewater⁷, shown comparable results of wastewater and clinical surveillance, and identified novel mutations and lineages before appearance in clinical samples 82. To date, wastewater sequencing of SARS-CoV-2 has not been widely applied in low or middle income countries. South Africa is a middle-income country with a population of over 55 million persons, most of whom live in urban centres located in five of the country's nine provinces. South Africa has over 1,000 wastewater treatment plants 9 and the majority of South Africans (84%) have access to piped sanitation (flush toilets connected to a public sewerage system or a septic tank) ¹⁰. Wastewater testing for SARS-CoV-2 was first described in South Africa in June 2020 11. The South African Collaborative

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

COVID-19 Environmental Surveillance System (SACCESS) arose to monitor trends in SARS-CoV-2 levels in wastewater 12. Most laboratory testing is provided to the public through an extensive network of laboratories including the National Health Laboratory Service (NHLS) that covers over 80% of the population. South Africa identified its first case of COVID-19 on the 5th of March 2020, 13 and four waves of COVID-19 occurred within the first 24 months of virus introduction into the country. Following the initial SARS-CoV-2 wave, the Beta variant ¹⁴ was discovered and was predominant from November 2020 to February 2021 (second wave). The third wave (May to September 2021) was characterized by the dominance of the Delta variant ¹⁵¹⁶ and the fourth wave (November 2021 to January 2022) by the Omicron BA.1 variant ¹⁷. The National Institute for Communicable Diseases (NICD), a division of the NHLS, provides SARS-CoV-2 epidemiological surveillance data through collation of SARS-CoV-2 PCR results from public and private laboratories. The Network for Genomics Surveillance in South Africa (NGS-SA) monitors the epidemiology of SARS-CoV-2 variants in PCR-confirmed cases in South Africa and reports weekly on findings ¹⁸. The NGS-SA provided the first global reports of the emergence of Beta and Omicron variants of concern (VOC) 1417. Here, we show that wastewater can be used to effectively characterize SARS-CoV-2 virus dynamics in the population and identify variants of concern present using samples from sentinel wastewater treatment plants in urban metros collected from April, 2021 to the end of the fourth wave in January, 2022, demonstrating the utility of wastewater genomic surveillance to complement clinical surveillance efforts in a middle income setting. We identify the potential strengths and limitations of genomic wastewater surveillance for SARS-CoV-2 in the South African context. Methods Wastewater sites A total of 325 samples were collected from 15 wastewater treatment plants (WWTP) in metropolitan areas also undergoing quantitative analysis of SARS-CoV-2 by the NICD 19. Sites were situated in Gauteng, Eastern Cape, Western Cape, Free State, and KwaZulu-Natal provinces. Supplementary table

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

S1 shows population sizes draining to each WWTP, and number of samples collected and sequenced. The samples were collected between April 2021 to January 2022 during the third and fourth waves of SARS-CoV-2 infections in South Africa. Sample collection, RNA extraction, amplification and sequencing One liter of grab sewage samples were collected and transported to NICD at 4°C. Viruses were concentrated from the sample by ultrafiltration ²⁰, and RNA was extracted using the QIAamp Viral RNA kit (Qiagen, GmbH, Germany). SARS-CoV-2 was detected by RT-PCR using the AllplexTM 2019-nCoV Assay from Seegene (Seoul, Korea). RNA was re-extracted from SARS-CoV-2 positive concentrates and subjected to amplicon-based whole genome sequencing using the Sinai protocol with some modifications as described ²¹ ²². Paired-end libraries were prepared using Illumina COVIDSeq Kit as previously described ²³ followed by sequencing (2x 150 pb) on NextSeq 1000/2000 platofrm (Illumina Inc, USA). Sequence analysis Quality control checks FastQ files were trimmed, filtered based on sequence quality, assembled and mapped to the reference genome (NC_045512.2) according to published criteria ²⁴ using Exatype web-based bioinformatics tool (https://sars-cov-2.exatype.com/). Quality control indicators such as number of reads, number of mapped reads, and sequence coverage were recorded. Samples that passed the internal quality control were processed for mutation analysis using ARTIC protocol (https://artic.network/ncov-2019/ncov2019-bioinformatics-sop.html) in Galaxy (https://usegalaxy.eu/) ²⁵. Again, reads were trimmed and filtered, assembled and mapped. At least 10 reads were required at each nucleotide position for downstream analysis. Amino acid mutations present at 5% of reads or less were removed from the analysis. Table 1 illustrates an example of amino acid variation analysis output. Sequence analysis using amino acid mutations Amino acids variation analysis

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

As SARS-CoV-2 RNA in wastewater is fragmented, and fragments originate from multiple individuals (generally infected with genetically distinct viruses), the generation of consensus sequences from wastewater samples is not meaningful. Rather, we inferred the presence of variants by using amino acid mutations uniquely associated with each VOC, as follows: Using the amino acid variation data file generated by the Galaxy pipeline above, we used STATA software (v 17.1) (https://www.stata.com/) to collate spike-gene mutations in a matrix such that the columns represented the amino acid positions of the spike protein and each row recorded mutations identified from a single wastewater sample. We included all mutations, and recorded the proportion of reads where that mutation was detected (the 'read frequency') as a percentage of total reads. For each VOC or Variant of Interest (VOI), we identified signature single amino acid mutations by comparing the new variant/ lineage with the Wuhan reference sequence in a public database ²⁶ (Table 2). Using this list of unique mutations for each VOC and VOI in the spike protein region (Table 2) we interrogated our matrix for the presence or absence of known signature mutations in each sample using STATA software. As new variants/lineages were detected and identified in clinical specimens, we added signature mutations to the STATA code, allowing us to identify the presence of new variants both retrospectively and prospectively. Heatmap and dot blot Using the amino acid variations data output file from Galaxy and the generated excel file that contains all amino acid variations and their respective read frequency, a heatmap was generated to identify patterns of emerging mutations in the spike gene using Excel conditional formatting. To identify the events and times at which uncommon mutations were identified in our samples, an in-house R script (R v.4.2.0) was used to generate a mutational dot plot. Analysis using the Freyia tool To capture the dynamics of virus evolution and spread, we used Freyja ²⁷, a tool to estimate the

relative abundance of virus lineages present in wastewater. Freyja uses a "barcode" library of lineagedefining mutations to uniquely define all known SARS-CoV-2 lineages and solves for lineage abundance using a depth-weighted, least absolute deviation regression approach. Freyja is free to use and available at https://github.com/andersen-lab/Freyja.

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

Results Quality control A total of 325 wastewater samples from sites listed in Table S1 were amplified and sequenced. The median number of sequence reads was 1.72x10⁶ (inter quartile range [IQR] 2.53X10⁵-2.67X10⁶) with a range of 6.5×10^4 to 8.16×10^6 reads (Figure S1). A total of 229 (70.5%) samples had > 1 million reads, and 237 (72.9%) samples had >50% reads mapped to the reference sequence (range 0-89%). Regarding sequence coverage in 10x depth, 183 (56.3%) samples had >50% sequence coverage of the whole genome (Figure S2a), and 177 (54.5%) samples had >50% sequence coverage in the spike region (Figure S2b). Detection of SARS-CoV-2 variants from wastewater samples using signature mutation analysis Signature mutations (Table 2) were identified in 170 samples (52.3%), 79 samples from Gauteng, 32 from KwaZulu-Natal, 32 Free State, 12 from Western Cape, and 15 from the Eastern Cape provinces respectively. Figure 1 illustrates the signature mutations for VOCs that were identified in samples from each wastewater treatment plant. In most of wastewater treatment plants a transition change in VOCs was observed in all wastewater treatment plants in the country, from Beta to Delta to Omicron during post second wave, third wave of fourth wave of infections. C.1.2 was also detected during Delta wave. Detection of SARS-CoV-2 variants from wastewater samples using Freyja tool Out of the 325 samples sequenced, 168 (51.7%) samples had a sequence coverage of >50% at 10x depth, and were successfully assigned a SARS-CoV-2 variant using the Freyja tool (Figure 2). In these samples, the Beta variant was detected and became predominate from April to June 2021. Delta variant emerge in May 2021 and predominates in June until October 2021. Omicron variant was detected in November 2021 and immediately dominate until January 2022. Alpha variant was seen in small proportion in June and July 2021 and lineage A and variant Kappa was detected in June 2021 in a very small proportion (Figure 2a). The proportions of lineages were shown in Figure 2b, a total of 68 lineages were detected of which 53 lineages were also reported in clinical cases and 15 lineages were not reported in clinical cases.

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

Characterization of amino acid mutations in the spike region A total of 411 amino acid mutations were observed in the spike protein amongst all sequenced samples. Alignment by amino acid position in a heatmap (Figure 3) demonstrated a characteristic pattern of mutations in each epidemiological wave of COVID-19. The transition from Delta variant to Omicron was characterized by a loss of mutations in the N-terminal domain (NTD) region (E156del, F157del, and R158G), and new mutations in the receptor binding (RBD) domain (G339D, S371L, 373, N440K, S477N, E484A, O493R, G496S, O498R), and fusion peptide (FP) region (N764K, D796Y), and the heptad repeat 1 (HR1) region (Q954H, N969K, L9811F). Between the third and fourth wave of infection low sequence coverage of spike was observed, likely due to low caseload, and few mutations were detected. Of the 411 substitutions/ deletions detected, 78 were present at >1% prevalence. When we compared those mutations to known published mutations at GISAID (https://gisaid.org/), 58 were commonly reported (Table S2), and 10 were uncommonly reported (Figure 4). **Discussion:** In this study, our sequencing methodology and bioinformatics pipeline facilitated detection and genomic characterization of SARS-CoV-2 lineages present in South African wastewater treatment plants in five provinces during the period April 2021 to January 2022. Our results showed the presence of all VOCs also detected amongst clinical samples (Beta, Delta, and Omicron). We detected amino acid mutations that were well-described and available publically in the GISAID database, and also amino acid mutations that were uncommon or rarely reported in clinical samples. We were also able to show the emergence of new mutations and loss of other mutations during the time of wave changes from Beta to Delta and from Delta to Omicron. Collectively, these findings illustrate how sequence analysis of SARS-CoV-2 in wastewater complements epidemiological findings based on clinical sequencing. Wastewater is a complex matrix containing highly fragmented virus genomic material. Our methodology generated a high number of reads with good quality and depth when compared to other studies that have sequenced SARS-CoV-2 from wastewater²⁸. In addition, the highest proportion of mapped reads was as 89% which was in the range of what have been achieved in other studies². The

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

highest sequence coverage in a depth of 10x reads in this study was 99% for the whole genome and spike protein. Our approach to interpretation of sequence data generated from wastewater samples is unlike analysis of sequences derived from clinical specimens. Because wastewater contains a mix of RNA fragments from viral particles originating from many infected individuals, the generation of consensus sequences is not meaningful. Our approach allows for identification of previously described variants in wastewater samples and also for detection of new patterns of mutations suggesting previously undescribed variants. Similarly, this approach has also been used Crits-Chritoph and colleague 8. Regarding detection of previously described variants in our wastewater samples, both approaches we used (mutational analysis and the Freyja tool) successfully identified lineages in wastewater that corresponded to lineages identified in clinical specimens ¹⁸. The Beta variant (first described in clinical specimens in South Africa in December 2020 14) was consistently observed from the start of wastewater surveillance until the end of the third wave in epidemiological week 19 (May 2021). Similarly, the Delta variant was first seen in clinical specimens during epidemiological week 21 of 2021 ¹⁶, and was first detected in wastewater samples the same week. Lineage C.1.2, described first in South Africa ²⁹ was successfully detected in sequences from wastewater samples during week 22 to 45 in 2021 whilst clinical detections of this lineage appeared from week 16 to 46. In epidemiological week 46 in 2021, the Omicron variant was identified in clinical samples whilst sequences from wastewater samples also identified mutations specific to Omicron in the same week. The Freyja tool ³⁰ complemented our mutational profile analysis, identifying the proportions of each variant/lineage in wastewater at specific time points. Results from Freyja comparable to the prevalence of VOCs of SARS-CoV-2 reported from clinical specimens and additionally indicate the presence of lineages in our wastewater samples that were absent amongst sequences from clinical cases. This most likely arises through the sampling bias inherent in clinical surveillance, in which only symptomatic patients

are tested and of whom only a fraction was sequenced.

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

Regarding detection of previously undescribed variants, our use of a spike-protein heatmap illustrated how each variant had a distinct mutational profile of RNA sequences of the spike gene, and that this changed in each wave. Through observation of the spike protein heatmap, samples with changing profiles may be identified before the new variant is sequenced from clinical isolates. This is clearly evident in the transition from the Delta to the Omicron variant, where a constellation of mutations in the NTD fell away and RBD, FP, and HR1 regions had new mutations (Figure 3). The shifting mutational profile correlated with the increased transmissibility of the Omicron variant that led to the fourth wave of infection in South Arfrica¹⁷. Our mutational analysis identified multiple instances of rare mutations in the population (Figure 4). These mutations were found at a prevalence of >1.0% in wastewater samples, but were detected at <0.001% in clinical cases based on the data from GISAID. Although they were uncommon, some mutations were reported previously. Mutation S50L was found to be associated with reduced protein stability ³¹. Mutation O498H has reportedly caused increased binding affinity of RBD to ACE2 ³². The presence of uncommon mutations could be explained as "cryptic lineages" as described by Smyth and colleagues ³³. In their paper they attributed the cryptic lineages to either un-sampled cases or spillover of SARS-CoV-2 from an unidentified animal reservoir. Other wastewater studies have demonstrated cryptic variants, for example Yaniv and colleagues described a cryptic Delta variant in wastewater samples ³⁴. Unusual substitutions /deletions are useful tools that support epidemiological tracking of variants and may support hypothesis generation regarding the origins of SARS-CoV-2. Sequencing of SARS-Cov-2 in wastewater currently has a number of limitations. Refining methodological approaches is essential in order to prevent inhibition from substances within the wastewater matrix. Where the incidence of SARS-CoV-2 is very low, virus concentration in wastewater may proceed below the level of detection, which makes it difficult to amplify and sequence the viral genome. Further, emergence of a new variants, such as Omicron sub-variants BA.1 and BA.2, can lead to poor primer binding and lower coverage rates, particularly in the spike protein because of S gene dropout ³⁵. Both of these scenarios renders sequencing of SARS-CoV-2 from wastewater challenging. In addition, bioinformatics methods for wastewater, including mutational

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

analysis and the Freyja tool, are currently limited by their reliance on lineage assignment based on prior clinical sequencing and publicly available sequences. Conclusion Sequencing of SARS-CoV-2 from wastewater largely corresponded with sequencing from clinical specimens. The prevalence of VOCs and lineages in clinical specimens was shown to be detectable in wastewater during the same times, which enabled us to provide comprehensive details on VOCs and lineages in the population. Despite inherent limitations of SARS-CoV-2 sampling in wastewater, we have generated a database spanning three SARS-CoV-2 waves, that document variant and lineage changes with time and geographical location and which correspond to clinically identified variants. We have illustrated how sequences not found in clinical specimens may be identified in populations through wastewater. Our heatmap has the potential to detect new variants prior to emergence in clinical samples and this may be particularly useful during times of low disease incidence between waves, when few numbers of positive clinical samples are collected and submitted for testing. Figure legends Figure 1 Signature mutation analysis of Variants of concern (VOC) and Variants of interest (VOI). The Y axis shows the read frequencies of each mutations, and X axis shows the epidemiological week when the samples were collected. The red line with dots shows the time-point analysed. Different shapes and colours of signature mutations were shown in the key. A-E: Gauteng province sites. E-G: KwaZulu-Natal province. H-I: Free State province. J-K: Western Cape province. L-O: Eastern Cape province. P: key for the different shapes and colours for each mutation and variants. Figure 2 The proportion of variants and lineages by month from wastewater samples, from April 2021 to January 2022 using the Freyja tool. The X-axis shows the month and the number of samples sequenced. The Y axis shows the proportion of each variant present in the specific month. Only samples with sequence coverage of >50 were included. "Other" represents unconfirmed lineages found in the

wastewater samples. A. SARS-CoV-2 variants. B. SARS-CoV-2 lineages

perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

Figure 3 Heatmap of amino acid mutations distributed across the SARS-CoV2 spike protein in comparison with the Wuhan reference strain, arranged vertically in chronological order. Each row represents a sample, organized by the date of sample collection. Each column represents an amino acid position of the spike protein. Regions with no mutations or low occurrences are represented in grey and light yellow (0-34%). Regions with mutations that have a 50% read frequency are represented in bright yellow. Regions with mutations with a read frequency between 60-80% are represented in orange and very high occurring mutations (89-100%) are represented in red, as per the key. Figure 4 Dot blot showing the uncommon mutations of SARS-CoV-2 detected in wastewater during the period April, 2021 – January, 2022 and their prevalence. The x-axis represents the uncommon mutations and the y-axis represents the times at which the mutations were first and last observed (as represented by continuous line between the dates). The size of the dot of each mutation describes the number of times the mutation was observed (prevalence) in the collected samples. **Declaration Ethics approval and consent to participant** The study did not involve any human participants. An application for ethics waiver was made to the Human Research Ethics Committee of the University of the Witwatersrand and was approved (number R14/49). **Consent for publication** Not applicable Availability of data and materials **Supplementary figures** Figure S1 Stacked graph illustrating the total number of sequence reads from wastewater samples (N = 325) between April, 2021 – January, 2022. Mapped reads are represented in blue and unmapped reads are represented in orange. A horizontal red line inserted at the mark one million reads. Samples had sequence reads of more than one million were to the left of the red vertical line and samples had

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

less than one million reads to the right of the red vertical line. The lower quartile value (2.53×10^5) , median (1.72x10⁶) and third quartile (2.6x10⁶) values are represented in blue horizontal broken lines. Figure S2. A graph showing the percentage coverage of SARS-CoV-2 in 10x depth of sequence reads. Y-axis is the percentage of coverage, and x-axis is the total number of samples. A. sequence coverage for whole genome. **B.** sequence coverage for spike protein. **Supplementary tables** Table S1, table S2, **Competing interests** All authors declare no competing interests. **Funding** We acknowledge the financial support from the National Institute for Communicable Diseases (NICD) of South Africa, the Water Research Commission (WRC) of South Africa, the German Society for International Cooperation (GIZ) and Bill and Melinda Gates foundation (BMGF), and Africa CDC. **Authors contributions** MY: co- conceptualized study, co- performed analysis, wrote, edit, and reviewed manuscript. SR: coconceptualized study, edit, and reviewed manuscript. ST: co- performed analysis, edit, and reviewed manuscript. NN: co- performed analysis, edit, and reviewed manuscript. CI: edit, and reviewed manuscript. WH: edit, and reviewed manuscript, SM: edit, and reviewed manuscript, SG: edit, and reviewed manuscript, JIL: co- performed analysis, edit, and reviewed manuscript, KGA: edit, and reviewed manuscript, CS: edit, and reviewed manuscript, AvG: edit, and reviewed manuscript, NW: edit, and reviewed manuscript AI: edit, and reviewed manuscript, MS: co- conceptualized, edit, and reviewed manuscript. KM: co- conceptualized, edit, and reviewed manuscript. Acknowledgements The authors would like to thank the local government and wastewater treatment staff for sample collection and transport. We also thank the staff of the NICD Centre for Vaccines and Immunology and

the Centre for Respiratory Disease and Meningitis. special thanks to: Josie Everatt, Boitshoko Mahlangu, Anele Mnguni, Noxolo Ntuli, Gerald Motsatsi for their assistance in setting up and troubleshooting PCR testing, and ongoing supportive collaboration. We thank the team at Hyrax Biosciences for the use of their tool exatype. We would like to acknowledge the contribution from the SACCESS network. We also acknowledge the funding from the NICD, Bill and Melinda Gates Foundation, Water Research Commission of South Africa, and Africa CDC.

References

347

348

349

350

351

352

353

- 1. Peng, L. *et al.* SARS-CoV-2 can be detected in urine, blood, anal swabs, and oropharyngeal swabs specimens. *J. Med. Virol.* **92**, 1676–1680 (2020).
- Fontenele, R. S. *et al.* High-throughput sequencing of SARS-CoV-2 in wastewater provides insights into circulating variants. *Water Res.* **205**, 117710 (2021).
- 358 3. The economist. How covid-19 spurred governments to snoop on sewage. (2022).
- 359 4. COVID19WBEC. COVID-19 WBE Collaborative. https://www.covid19wbec.org/ (2020).
- 360 5. Zhu, N. *et al.* A novel coronavirus from patients with pneumonia in China, 2019. *N. Engl. J.*
- 361 *Med.* (2020).
- Wang, W. et al. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. JAMA
 323, 1843–1844 (2020).
- Lara, R. W. I. *et al.* Monitoring SARS-CoV-2 circulation and diversity through community
 wastewater sequencing. *medRxiv* (2020).
- Crits-Christoph, A. *et al.* Genome sequencing of sewage detects regionally prevalent SARS CoV-2 variants. *MBio* 12, e02703-20 (2021).
- 368 9. DWS. NATIONAL INTEGRATED WATER INFORMATION SYSTEM.
- https://www.dws.gov.za/niwis2?AspxAutoDetectCookieSupport=1 (2022).
- 370 10. STATS SA. Stats SA General Household Survey 2021. https://www.statssa.gov.za/?p=15482

371 (2021).11. Johnson, R. et al. Qualitative and quantitative detection of SARS-CoV-2 RNA from untreated 372 373 wastewater in the Western Cape, South Africa. Methodol. Detect. SARS COV 2 RNA lN 374 WASTEWATER SURVEILLANCE 52 (2020). 375 12. NICD. WASTEWATER-BASED EPIDEMIOLOGY FOR SARS-COV-2 IN SOUTH 376 AFRICA INCLUDING WASTEWATER GENOMICS. https://www.nicd.ac.za/diseases-a-zindex/disease-index-covid-19/surveillance-reports/weekly-reports/wastewater-based-377 epidemiology-for-sars-cov-2-in-south-africa/(2022). 378 NICD. FIRST CASE OF COVID-19 CORONAVIRUS REPORTED IN SA. 379 13. 380 https://www.nicd.ac.za/first-case-of-covid-19-coronavirus-reported-in-sa/ (2020). 381 14. Tegally, H. et al. Emergence and rapid spread of a new severe acute respiratory syndromerelated coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. 382 383 MedRxiv (2020). 384 15. ECDC. Brief, Threat Assessment: Emergence of SARS-CoV-2 B. 1.617 variants in India and 385 situation in the EU/EEA. (2021). 386 16. Tegally, H. et al. Rapid replacement of the Beta variant by the Delta variant in South Africa. 387 MedRxiv (2021). 388 17. Karim, S. S. A. & Karim, Q. A. Omicron SARS-CoV-2 variant: a new chapter in the COVID-389 19 pandemic. Lancet 398, 2126–2128 (2021). NICD. Network for Genomic Surveillance in South Africa (NGS-SA). SARS-CoV-2 390 18. 391 Sequencing Update 19 August 2022. (2022). 392 19. Iwu-Jaja, C., Dlovu, KL., Said, R., Yousif, M., Taukobong, S., Macheka, M., Mhlanga, L., van Schalkwyk, C., Pulliam, J., Moultrie, T., Suchard, M., McCarthy, K. Cumulative evidence 393 from the South African COVID Collaborative Environmental Surveillance System 394 395 (SACCESS) supports reliance on wastewater-based epidemiological approaches for COVID

- pandemic monitoring in a middle income African country. In preparation.
- 397 20. Ikner, L. A., Soto-Beltran, M. & Bright, K. R. New method using a positively charged
- microporous filter and ultrafiltration for concentration of viruses from tap water. *Appl.*
- 399 Environ. Microbiol. 77, 3500–3506 (2011).
- 400 21. Rachida, S. Validating the COVIDSeq and Sinai protocols for wastewater-based sequencing of
- 401 *SARS-CoV-2. In preparation.*
- 402 22. Gonzalez-Reiche, A. S. et al. Introductions and early spread of SARS-CoV-2 in the New York
- 403 City area. *Science* (80-.). **369**, 297–301 (2020).
- 404 23. Bhoyar, R. C. et al. High throughput detection and genetic epidemiology of SARS-CoV-2
- using COVIDSeq next-generation sequencing. *PLoS One* **16**, e0247115 (2021).
- 406 24. Khailany, R. A., Safdar, M. & Ozaslan, M. Genomic characterization of a novel SARS-CoV-2.
- 407 Gene reports 19, 100682 (2020).
- 408 25. Afgan, E. et al. The Galaxy platform for accessible, reproducible and collaborative biomedical
- analyses: 2016 update. *Nucleic Acids Res.* **44**, W3–W10 (2016).
- 410 26. Gangavarapu, K. et al. Outbreak. info genomic reports: scalable and dynamic surveillance of
- 411 SARS-CoV-2 variants and mutations. *medRxiv* (2022).
- 412 27. Karthikeyan, S. et al. Wastewater sequencing reveals early cryptic SARS-CoV-2 variant
- 413 transmission. *Nature* **609**, 101–108 (2022).
- 414 28. Lou, E. G. et al. Direct comparison of RT-ddPCR and targeted amplicon sequencing for
- 415 SARS-CoV-2 mutation monitoring in wastewater. Sci. Total Environ. 833, 155059 (2022).
- 416 29. Scheepers, C. et al. Emergence and phenotypic characterization of C. 1.2, a globally detected
- 417 lineage that rapidly accumulated mutations of concern. (2021).
- 418 30. Karthikeyan, S. et al. Wastewater sequencing uncovers early, cryptic SARS-CoV-2 variant
- 419 transmission. medRxiv (2021).

421

422

423

424

425

426

427

428

429

430

431

432

31. Laha, S. et al. Characterizations of SARS-CoV-2 mutational profile, spike protein stability and viral transmission. Infect. Genet. Evol. 85, 104445 (2020). Bate, N. et al. In vitro evolution predicts emerging SARS-CoV-2 mutations with high affinity 32. for ACE2 and cross-species binding. *PLoS Pathog.* **18**, e1010733 (2022). 33. Smyth, D. S. et al. Tracking cryptic SARS-CoV-2 lineages detected in NYC wastewater. Nat. Commun. 13, 1–9 (2022). 34. Yaniv, K. et al. Managing an evolving pandemic: Cryptic circulation of the Delta variant during the Omicron rise. Sci. Total Environ. 836, 155599 (2022). WHO. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern. 35. https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2variant-of-concern (2021).

Table 1. Illustration of amino acid variations in samples, produced by the Galaxy pipeline.

433

434

435

436

437

438

Α	В	С	D	E	F	G
Sampl e	QC filter	Numb er of reads	Mutation effect	GENE	Mutatio n	Mutatio n frequen cy
21- 0128	PASS	4073	NON_SYNONYMOUS_COD ING	ORF1a b	E41K	92
21- 0128	PASS	12106	NON_SYNONYMOUS_COD ING	S	L1203F	96
21- 0128	min_af_0.1Xmin_ dp_5Xmin_dp_alt _10	12234	FRAME_SHIFT	S	V1228	1
21- 0128	PASS	13569	NON_SYNONYMOUS_COD ING	ORF3a	T190I	88
21- 0128	PASS	1536	NON_SYNONYMOUS_COD ING	E	P71L	97
21- 0128	min_af_0.1Xmin_ dp_5Xmin_dp_alt _10	1339	NON_SYNONYMOUS_COD ING	М	185	1

A shows sample ID. B is the quality indicator. Filter value 'PASS' are samples with a minimum of 10 reads and read frequency greater than 10. C is the number of reads produced for each sample. D is the effect of the mutation detected in the gene. **E** is the name of the gene where mutation occurred. **F** is the mutation detected. **G** is the proportion of the mutant cells in a sample or population.

Table 2: List of signature mutations which was used to identify VOC and VOI present in wastewater samples (Gangavarapu et al., 2022)

Omicron	Alpha	Beta	Delta	C.1.2	Gamma	Lambda	Mu
G339D	A570D	D80A	T19R	P9L	T20N	G75V	Y144S
S371L	S982A		R145H	P25L	P26S	T76I	Y145N
S375F	D1118H		E156del	C136F	T1027I	D253N	
Q493R			R158G	Y449H		L452Q	
G496S			A222V			F490S	
Y505H							
T547K							
N856K							
Q954H							
N969K							
L981F							








Figure 1 A-E














Figure 2A




Figure 2B





Figure 3



S50L 5 1,54 H66Y 27 8,31 Y144-20 6,15 T250S 10 3,08 A288T 13 4,00 K444T 4 1,23 N460K 5 1,54 Q498H 2,77 9 6,77 D627H 22 L828F 13 4,00 T859N 4,31 14 D1153A 16 4,92 D1153Y 2,46 8 Q1201 1,23 4

Number of samples

detected in Wastewater

Mutation

Prevalence in

wastewater South

Africa (N = 325)

Figure 4